Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|2|3|163-168

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.2, Iss.3, 2007-09, pp. : 163-168

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome

By  

Current Signal Transduction Therapy, Vol. 7, Iss. 3, 2012-09 ,pp. : 265-288

Bentham Science Publishers

Access to resources Recommend Favorite

A Complete Response Case in a Patient with Multiple Lung Metastases of Rectal Cancer Treated with Bevacizumab plus XELIRI Therapy

By  

Case Reports in Oncology, Vol. 10, Iss. 1, 2017-01 ,pp. : 81-85

Karger

Access to resources Recommend Favorite

Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study

By  

Oncology, Vol. 83, Iss. 3, 2012-08 ,pp. : 151-157

Karger

Access to resources Recommend Favorite

Possible Rationale for Procaine (Gerovital H3) Therapy in Geriatrics: Inhibition of Monoamine Oxidase

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 21, Iss. 9, 1973-09 ,pp. : 414-418

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-05 ,pp. : 363-367

Karger

Access to resources Recommend Favorite